Sorafenib is a multikinase inhibitor capable of facilitating apoptosis, mitigating angiogenesis
and suppressing tumor cell proliferation. In late-stage hepatocellular carcinoma (HCC) …

Sorafenib, an orally-available kinase inhibitor, is the only standard clinical treatment against
advanced hepatocellular carcinoma. However, development of resistance to sorafenib has …

Sorafenib is the standard first-line systemic drug for advanced hepatocellular carcinoma
(HCC), but the acquired resistance to sorafenib results in limited benefits. Activation of Akt is …

Tumor-infiltrating leukocytes are often induced by the cancer microenvironment to display a
protumor, proangiogenic phenotype. This “polarization” has been described for several …

Our understanding of the dynamic tumor microenvironment (TME) has improved
exponentially over the last few decades. In addition to traditional cytotoxic agents, anti …

Liver cancer is highly malignant and insensitive to cytotoxic chemotherapy and is associated
with very poor patient prognosis. In 2007, the small-molecule targeted drug sorafenib was …

Liver cancer, mostly hepatocellular carcinoma (HCC), is the second leading cause of cancer
mortality globally. Most patients were diagnosed at an advanced stage, and systemic …

A recurrence of hepatocellular carcinoma (HCC) after living donor liver transplantation
(LDLT) is one of the major concerns reflecting the higher mortality of HCC. This study aimed …

Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide.
Tyrosine kinase inhibitors (TKIs) remain the backbone of systematic therapy for advanced …

Recent experiments have evidenced sub-nanometer resolution in plasmonic-enhanced
probe spectroscopy. Such a high resolution cannot be simply explained using the commonly …